ENGOT-EN6/NSGO-RUBY

Trial Description: 
A Phase 3, randomized, double-blind, multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in patients with reurrent or primary advanced endometrial cancer
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Endometrial
Trial Status: 
Recruitment Pending
Contact person: